USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, QUINARETIC should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
QUINARETIC is a fixed-combination tablet that combines an angiotensin-converting enzyme (ACE) inhibitor, quinapril hydrochloride, and a thiazide diuretic, hydrochlorothiazide.
QUINARETIC is indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).
In using QUINARETIC, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis).
Angioedema in Black Patients:
Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.
Media Articles Related to Quinaretic (Quinapril / Hydrochlorothiazide)
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2013.11.25]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/25/2013 12:00:00 AM
Increased risk of alcohol-related hypertension in individuals who flush after drinking
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2013.11.21]
Excessive drinking is a known risk factor for hypertension. Drinking that results in facial flushing indicates high sensitivity or even intolerance to alcohol. A study of the relationship between drinking and these two conditions has found that drinking-related hypertension has a lower threshold value and higher risk in flushers than in non-flushers.
Some allergy suffers with hypertension may be at increased risk for severe reaction
Source: Allergy News From Medical News Today [2013.11.12]
Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.
In low-income urban neighborhoods the rates of diabetes, hypertension, heart disease and stroke are much higher
Source: Hypertension News From Medical News Today [2013.11.07]
There is more to the cost of living in a food desert than higher prices for the few fruits and vegetables sold nearby, according to a study by an Indiana University-Purdue University Indianapolis researcher and the Marion County Public Health Department.
Further positive Opsumit (macitentan) data in pulmonary arterial hypertension presented at CHEST 2013
Source: Hypertension News From Medical News Today [2013.10.31]
Actelion (SIX: ATLN) has announced that following the recent FDA approval and positive CHMP opinion for macitentan (Opsumit®) in pulmonary arterial hypertension (PAH), further positive data on the efficacy of macitentan from the SERAPHIN study were presented at CHEST 2013 in Chicago, USA (26-31 October 2013).
Clinical Trials Related to Quinaretic (Quinapril / Hydrochlorothiazide)
Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF [Recruiting]
Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in
numerous hospitalizations. Catheter ablation is a technique that has evolved significantly
to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize
that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter
ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus
standard BP control to investigate this. The primary outcome will be time to recurrent AF.
Page last updated: 2013-11-25